Reply: Association between triple therapy and major adverse cardiovascular events in COPD patients

We thank P. Almagro and P. Martinez-Camblor for their interest in our work and for their salient comments. While we agree that there is no universally accepted definition of major adverse cardiovascular event (MACE), the US Food and Drug Administration (FDA) and the European Medicines Agency include nonfatal myocardial infarction and stroke as well as cardiovascular (CV) mortality in their MACE definition [1]. Importantly, this definition includes both haemorrhagic and ischaemic stroke [1–4]. In our study, we followed this classical "three-point" definition of MACE (including haemorrhagic strokes). While this definition has been by far the most commonly used one in clinical trials and other studies for evaluation of CV therapeutics and interventions, we agree with P. Almagro and P. Martinez-Camblor that there remains significant debate in the community on the merits of this definition, with others proffering alternate definitions of MACE [1].

Source: European Respiratory Journal - March 2, 2023 Category: Respiratory Medicine Authors: Yang, M.-J., Guo, S.-L., Sin, D. D. Tags: Correspondence Source Type: research